Key Takeaways Immunovant rose 10.8% on six-month off-treatment results for batoclimab in Graves' disease.About 80% of patients maintained normalized thyroid hormone levels during follow-up.IMVT aims to use these results to accelerate the development of lead candidate IMVT-1402 in GD.Immunovant, Inc. (IMVT) shares gained 10.8% on Wednesday after the company announced new six-month off-treatment results from a proof-of-concept study evaluating its investigational candidate, batoclimab, in patients with uncont ...